Candriam expands biotech team

Candriam Investors has expanded its Brussels-based biotech equity strategy team with the appointment of Servaas Michielssens as senior biotechnology analyst.

Michielssens spent the last two years at the Max Planck Institute in Germany, where he developed computational protocols serving research of biomolecules with improved properties. He holds a Master in Computational Chemistry and a PhD in Science from the KU Leuven.

Based in Brussels, he will now be in charge of analysing the latest trends on drugs that are being developed for the $500bn Candriam Equities L Biotechnology fund.

“Servaas Michielssens had great knowledge of small molecule drug development and this is complementary with the other team members who are more protein drug specialists”, comments Rudi Van den Eynde, head of Thematic Global Equity at Candriam.

ABOUT THE AUTHOR
Mona Dohle
Mona Dohle speaks German and Dutch, she is DACH & Benelux Correspondent for InvestmentEurope. Prior to that, she worked as a journalist in Egypt and Palestine. She started her career as a journalist working for a local German newspaper. Mona graduated with an MSc in Development Studies from SOAS and has completed the CISI Certificate in International Wealth and Investment Management.

Read more from Mona Dohle

preloader
Close Window
View the Magazine





You need to fill all required fields!